2024
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1
Exposito F, Redrado M, Serrano D, Calabuig-Fariñas S, Bao-Caamano A, Gallach S, Jantus-Lewintre E, Diaz-Lagares A, Rodriguez-Casanova A, Sandoval J, San Jose-Eneriz E, Garcia J, Redin E, Senent Y, Leon S, Pio R, Lopez R, Oyarzabal J, Pineda-Lucena A, Agirre X, Montuenga L, Prosper F, Calvo A. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1. Cell Death & Disease 2024, 15: 787. PMID: 39488528, PMCID: PMC11531574, DOI: 10.1038/s41419-024-07156-w.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNon-small cell lung cancer patientsCM-272Treatment of non-small cell lung cancerReprogram tumor cellsAssociated with poor prognosisResponse to chemotherapyCell lung cancerCancer drugsMonitor tumor progressionOverexpression of G9aNSCLC cell linesLung cancer growthCancer drug sensitivityNon-small cell lung cancer growthNon-invasive biomarkersTumor volumeAntitumor efficacyTargeted therapyPoor prognosisCancer modelsTumor cellsInduce cell deathTumor progressionLung cancer
2020
In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer
Luis de Redín I, Expósito F, Agüeros M, Collantes M, Peñuelas I, Allemandi D, Llabot JM, Calvo A, Irache JM. In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer. Drug Delivery And Translational Research 2020, 10: 635-645. PMID: 32040774, DOI: 10.1007/s13346-020-00722-7.Peer-Reviewed Original ResearchConceptsAlbumin nanoparticlesHuman serum albumin nanoparticlesAlbumin-based nanoparticlesSerum albumin nanoparticlesPoor tumor penetrationNanoparticlesColorectal cancerTumor penetrationFree bevacizumabXenograft modelAdequate carrierMean sizeHT-29 xenograft modelMetabolic tumor volumePotential undesirable side effectsHuman colorectal cancerTumor growth rateConventional formulationUndesirable side effectsLower incidenceTumor volumeBevacizumabEffective treatmentSide effectsVivo efficacy